Congress should encourage the Centers for Medicare and Medicaid Services to clarify that Medicaid programs have the authority to reimburse hospitals for cell and gene therapy outside the typical payment bundle, the Alliance for Regenerative Medicine recommended in comments to Senate Health, Education Labor and Pensions ranking Republican Bill Cassidy, LA.
Key Takeaways
-
Separate Medicaid payments to hospitals for cell and gene therapy could increase payment amounts and uptake by providers, ARM said.
-
Congress should enact legislation to provide enhanced funding for separate payments for the treatment through increased federal matching, the group urged.
-
CMMI’s planned payment demonstration for facilitating uptake of cell and gene therapies covered by Medicaid could be helpful, but a broader policy approach is still needed, according to ARM
The comments respond to a request for information issued by Cassidy in early December
